Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT + Ipilimumab N01 + Sintilimab + AG Chemotherapy in Locally Advanced Pancreatic Cancer
NCT07683221Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab, sintilimab in pancreatic cancer (PC), sponsored by Shandong Cancer Hospital. Started Aug 2026; status: recruiting.
02
Drugs
ipilimumabsintilimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07683221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683221.